Literature DB >> 23329715

An unexpected diagnosis in a dyspnoeic patient with primary Sjogren syndrome.

Ali Raza Rajani1, Kosar Hussain, Fahad Omar Baslaib, Kabad N S Rao.   

Abstract

We describe a case of a 50-year-old lady with newly diagnosed primary Sjogren syndrome who presented with severe pulmonary artery hypertension and pericardial effusion. She was managed by immunosuppressive agents and a combination of standard therapy for pulmonary hypertension. Our patient had a clinically significant involvement of cardio-pulmonary system that is atypical of this disease. Prompt recognition and management of this condition are extremely crucial as untreated cases carry a grave prognosis. However, the ideal treatment strategy is yet to be defined for this condition.

Entities:  

Mesh:

Year:  2013        PMID: 23329715      PMCID: PMC3604290          DOI: 10.1136/bcr-2012-007819

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Vallerie V McLaughlin; Kenneth W Presberg; Ramona L Doyle; Steven H Abman; Douglas C McCrory; Terry Fortin; Gregory Ahearn
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

3.  [Pulmonary arterial hypertension and Sjögren's syndrome: and uncommon association].

Authors:  Manuel Vallalta Morales; Luisa Micó Giner; María Luisa Muñoz Guillem; José Ramón Calabuig Alborch
Journal:  Med Clin (Barc)       Date:  2004-11-27       Impact factor: 1.725

4.  Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension.

Authors:  Y Kamata; H Nara; H Sato; J-I Masuyama; S Minota; T Yoshio
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

5.  Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.

Authors:  David Montani; Laurent Savale; Delphine Natali; Xavier Jaïs; Philippe Herve; Gilles Garcia; Marc Humbert; Gérald Simonneau; Olivier Sitbon
Journal:  Eur Heart J       Date:  2010-06-11       Impact factor: 29.983

6.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.

Authors:  Ronald J Raymond; Alan L Hinderliter; Park W Willis; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Todd Schwartz; Gary Koch; Linda M Clayton; Maria M Jöbsis; James W Crow; Walker Long
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

Review 7.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

Review 8.  Pulmonary hypertension associated with connective tissue disease.

Authors:  Karen A Fagan; David B Badesch
Journal:  Prog Cardiovasc Dis       Date:  2002 Nov-Dec       Impact factor: 8.194

9.  Is the heart affected in primary Sjögren's syndrome? An echocardiographic study.

Authors:  V A Vassiliou; I Moyssakis; K A Boki; H M Moutsopoulos
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

10.  Neurological Disorders in Primary Sjögren's Syndrome.

Authors:  Gabriel J Tobón; Jacques-Olivier Pers; Valérie Devauchelle-Pensec; Pierre Youinou
Journal:  Autoimmune Dis       Date:  2012-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.